Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Company Drug

Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC

Fineline Cube Sep 6, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical...

Company Deals

Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem

Fineline Cube Sep 6, 2022

Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo...

Company Deals

Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device

Fineline Cube Sep 6, 2022

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...

Company Deals

HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target

Fineline Cube Sep 6, 2022

China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...

Company Drug

Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial

Fineline Cube Sep 6, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19...

Company Drug

Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch

Fineline Cube Sep 6, 2022

Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...

Company Deals

CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development

Fineline Cube Sep 6, 2022

CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has...

Company Deals

Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies

Fineline Cube Sep 6, 2022

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...

Company Deals

Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million

Fineline Cube Sep 6, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...

Company Drug

SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC

Fineline Cube Sep 6, 2022

China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...

Company Medical Device

Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits

Fineline Cube Sep 6, 2022

Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United...

Company Drug

Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC

Fineline Cube Sep 6, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...

R&D

BGI’s Stereo-seq Tech Maps Axolotl Brain Regeneration in World-First Study

Fineline Cube Sep 5, 2022

China’s genomics giant BGI has revealed a landmark study using its proprietary Stereo-seq sequencing technology...

Company Drug

Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL

Fineline Cube Sep 5, 2022

US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first...

Company Deals

Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion

Fineline Cube Sep 5, 2022

China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...

Company Drug

CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines

Fineline Cube Sep 5, 2022

China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...

Company Deals Digital

AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center

Fineline Cube Sep 5, 2022

Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...

Company Deals

BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion

Fineline Cube Sep 5, 2022

China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata

Fineline Cube Sep 5, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy

Fineline Cube Sep 5, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Posts pagination

1 … 619 620 621 … 657

Recent updates

  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.